Compare · INFI vs MRK
INFI vs MRK
Side-by-side comparison of Infinity Pharmaceuticals Inc. (INFI) and Merck & Company Inc. (MRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INFI and MRK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK carries a market cap of $339.66B.
- MRK has hit the wire 24 times in the past 4 weeks while INFI has been quiet.
- MRK has more recent analyst coverage (25 ratings vs 4 for INFI).
- Company
- Infinity Pharmaceuticals Inc.
- Merck & Company Inc.
- Price
- -
- -
- Market cap
- -
- $339.66B
- 1M return
- -
- -7.05%
- 1Y return
- -
- +45.00%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 24
- Recent ratings
- 4
- 25
Infinity Pharmaceuticals Inc.
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 1/1b clinical trials for the treatment of triple negative breast cancer, solid tumors, and ovarian cancer. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Cambridge, Massachusetts.
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest INFI
- Infinity Pharmaceuticals Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Leadership Update
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- Why Eiger BioPharmaceuticals Shares Are Trading Lower By 52%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Infinity Pharmaceuticals Received A Delisting Determination Letter From Nasdaq Stating That The Company's Stock Will Be Suspended On September 14, Unless It Requests A Review Of This Decision
- Infinity Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 4: Perkins Adelene Q converted options into 768,133 shares and sold $28,714 worth of shares (410,196 units at $0.07), increasing direct ownership by 44% to 1,175,291 units
- Infinity Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Infinity Pharmaceuticals Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update, Other Events
Latest MRK
- Merck and Isomorphic Labs Enter Strategic Research Collaboration
- Merck & Company Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Thomas H. Glocer to Retire From Merck Board of Directors in May 2027; Douglas M. Baker, Jr. Appointed Independent Lead Director
- Merck Announces Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib
- Merck Announces First-Quarter 2027 Dividend
- EVP&Pres, Merck Animal Heallth Deluca Richard R. exercised 58,185 shares at a strike of $77.62 and sold $8,611,875 worth of shares (58,185 units at $148.01), decreasing direct ownership by 0.00% to 112,955 units (SEC Form 4)
- SEC Form 13F-HR filed by Merck & Company Inc.
- Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
- Merck to Participate in the Jefferies Global Healthcare Conference in London
- Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis